Thomas Mandrup-Poulsen

Summary

Country: Denmark

Publications

  1. doi Interleukin-1 antagonists for diabetes
    Thomas Mandrup-Poulsen
    University of Copenhagen, Panum Institute 12 2 10, Faculty of Health and Medical Sciences, Department of Biomedical Sciences, Section for Endocrinological Research, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 22:965-79. 2013
  2. pmc Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    Rev Diabet Stud 9:338-47. 2012
  3. doi Type 2 diabetes mellitus: a metabolic autoinflammatory disease
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3 Blegdamsvej, DK 2200 Copenhagen N, Denmark
    Dermatol Clin 31:495-506. 2013

Detail Information

Publications4

  1. doi Interleukin-1 antagonists for diabetes
    Thomas Mandrup-Poulsen
    University of Copenhagen, Panum Institute 12 2 10, Faculty of Health and Medical Sciences, Department of Biomedical Sciences, Section for Endocrinological Research, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 22:965-79. 2013
    ..There is an unmet need for interventions targeting pathogenetic mechanisms in diabetes, and the market for such therapies is huge...
  2. pmc Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    Rev Diabet Stud 9:338-47. 2012
    ....
  3. doi Type 2 diabetes mellitus: a metabolic autoinflammatory disease
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3 Blegdamsvej, DK 2200 Copenhagen N, Denmark
    Dermatol Clin 31:495-506. 2013
    ..It is hoped that targeting these mechanisms will enable the introduction of novel therapies that attack the basic pathogenetic mechanisms of type 2 diabetes mellitus rather than the epiphenomena that are its consequences. ..